MacroGenics, Inc. — FY2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. The filing also reports fourth-quarter results. MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based medicines; it had no approved products and no product-sales revenue.
Financial performance and liquidity
| Metric | FY2015 | FY2014 |
|---|---|---|
| Total revenue | $100.9 million | $47.8 million |
| Research and development expense | $98.3 million | $70.2 million |
| General and administrative expense | $22.8 million | $15.9 million |
| Operating loss | $20.2 million | $38.3 million |
| Net loss | $20.1 million | $38.3 million |
| Net loss per diluted share | $0.63 | $1.40 |
| Cash, cash equivalents and investments at year-end | $339.0 million | $157.6 million |
| Operating cash flow | $(13.7) million | $(32.8) million |
Collaboration revenue was $99.4 million, with $1.5 million from government agreements. Janssen accounted for approximately 71.7% of total revenue. FY2015 revenue included $72.3 million recognized under the Janssen agreement, including an upfront payment and milestone-related amounts; revenue is therefore collaboration-dependent and can vary with contract accounting and milestones.
Fourth-quarter 2015 revenue was $8.2 million and net loss was $28.5 million, or $0.83 per share. The first-quarter net income reported for 2015 was driven by collaboration revenue recognition, rather than product sales.
Current assets were $342.4 million and current liabilities $23.3 million at year-end. Total liabilities were $45.9 million; the filing reports no borrowings or funded debt. The company reported $313.3 million in stockholders’ equity. Financing cash flow was $204.3 million, principally reflecting equity proceeds, including a $75 million investment by a Johnson & Johnson affiliate and a follow-on offering.
Material changes versus FY2014
- Revenue rose 111%, mainly due to Janssen-related revenue; collaboration revenue from several other partners declined or ended as related development periods concluded.
- R&D expense increased 40%, led by the start of the Phase 3 SOPHIA trial for margetuximab, combination studies, MGD010 clinical work and preclinical checkpoint programs.
- G&A expense increased 44%, mainly due to labor, stock compensation and information-technology costs.
- Net loss narrowed by $18.2 million, while cash and investments more than doubled, substantially supported by equity financing.
Pipeline, outlook and principal risks
- Margetuximab entered Phase 3 testing for HER2-positive metastatic breast cancer; the company also began a combination study with pembrolizumab. Other clinical programs included enoblituzumab and DART candidates MGD006, MGD007, MGD009, MGD010 and partner-led MGD011.
- Management expected year-end cash, cash equivalents and investments, plus anticipated collaboration payments, to fund operations into 2018, assuming collaboration programs progressed as planned. The company expected operating expenses to increase and did not forecast profitability.
- All candidates remained in preclinical or clinical development; trial outcomes, regulatory approval, patient enrollment, manufacturing scale-up and commercial acceptance were uncertain. MacroGenics had no established sales and marketing infrastructure.
- Funding and revenue depend in part on collaborators’ performance, option decisions and achievement of milestones. Janssen represented a material revenue concentration in 2015.
- Manufacturing capacity and reliance on contract manufacturers create supply and execution risks, particularly for later-stage trials and any future commercialization. Competition, reimbursement and biosimilar pricing could limit market opportunity.
- Potential intellectual-property disputes include third-party patents covering Fc-engineering methods and mutations relevant to margetuximab and enoblituzumab; the company stated it believed certain patents were invalid, but outcomes were uncertain.
- Operating lease commitments totaled $27.8 million. Additional contingent Raven acquisition payments include a potential $5 million payment upon qualifying Phase 2 dosing, plus sales-related payments; timing and likelihood are uncertain. No material legal proceedings were reported.
- The company reported effective disclosure controls and internal control over financial reporting; the auditor issued unqualified opinions on the financial statements and internal controls.
Key facts for investors to verify
- Progress, enrollment, safety and efficacy milestones in SOPHIA and other clinical trials, and any regulatory guidance or changes to trial timelines.
- Cash burn and the stated runway into 2018, including how dependent it is on anticipated partner payments and program assumptions.
- Composition and sustainability of collaboration revenue, Janssen concentration, partner options and milestone conditions.
- Manufacturing expansion schedule, contract-manufacturer capacity and costs, and readiness for later-stage margetuximab supply.
- Current status of relevant Fc-engineering intellectual-property claims, and potential contingent Raven obligations.